INTRODUCTION
Inflammatory bowel disease (IBD) is a group of chronic, r e l ap s i n g , i n f l a m m at o r y disorders of the gastrointestinal tract. Ulcerative colitis (UC) and Crohn's disease (CD) are the principal types of IBD [1] . According to the most widely accepted hypothesis, environmental factors may trigger IBD onset in individuals with genetic susceptibility by altering the intestinal mucosal barrier and the healthy balance of the gut microbiota, resulting in an aberrant immune response of the gut [2] . Recently, an association of IBD with changes in gut microbiota composition has been reported [3] , but no mechanistic explanation for this association has been provided [4] .
Helicobacter species are gram-negative curved or spiral bacteria. Depending on the site of the gastrointestinal tract colonized, Helicobacter species are divided into entero-hepatic Helicobacters (EHH) and gastric Helicobacters [5] . Different studies have investigated the association between IBD and Helicobacter species. In case-control studies, both UC [6] and CD [7] were associated with the presence of EHH species DNA in intestinal biopsies.
Helicobacter species dominate the microbiota community of the gastric mucosa and influence duodenal and oral communities [8] . Helicobacter pylori (H. pylori) is typically acquired during early childhood and causes a chronic active gastritis in the infected subject. A subset of subjects with H.
J Gastrointestin Liver Dis, June 2018 Vol. 27 No 2: 119-125 pylori gastritis may develop peptic ulcer disease, gastric cancer or MALT-lymphoma. Various studies have consistently shown a low H. pylori seroprevalence in patients with IBD, suggesting a protective role of this infection for the development of IBD [9] . Recently, IBD onset after successful H. pylori eradication therapy has been reported in three clinical cases [10] [11] [12] . Accordingly, the hypothesis that profound changes of the intestinal microbiota induced by eradication therapy (i.e. a combination of two antibiotics and a proton pump inhibitor) may trigger IBD appears attractive. On the other hand, the loss of H. pylori induced immune response may play a role in increasing the susceptibility to develop IBD as well. These aspects may lead to anxiety in patients and even induce the physician to refrain from prescribing appropriate H. pylori eradication therapy. The aim of the present study was to investigate whether previous H. pylori eradication therapy may be associated with an increased risk of developing IBD.
METHODS

Study design and study population
The primary aim of the present study was to evaluate whether previous H. pylori eradication therapy may represent a risk factor for developing IBD. For answering this question we chose a case-control study design. The prevalence of previous H. pylori eradication therapy -the putative risk factor -was studied in IBD patients (cases) and controls.
Patients with IBD were enrolled between December 2016 and May 2017 at the outpatient Department of Gastroenterology, Hepatology and Infectious Diseases at the Otto-von-Guericke University (Magdeburg, Germany). In our clinic, biological therapy for IBD patients is scheduled on Fridays (ca. 25 patients per day). To simplify the recruitment, only IBD patients receiving a biological therapy (i.e. Infliximab, Vedolizumab, Ustekinumab) were enrolled.
Sex-and age-matched (± 5 years) controls were selected from a cohort of 516 consecutive healthy blood donors that were enrolled between May and June 2016 in a prospective epidemiological study on the seroprevalence of H. pylori infection in Saxony-Anhalt [13] .
Patients and controls were interviewed using the same structured questionnaire that comprised information on demographics, number of siblings, medical history and previous H. pylori eradication therapy. Study participants with previous H. pylori eradication therapy provided records of the eradication including the regimen used for eradication therapy and the test performed to confirm successful eradication.
In patients with IBD disease, onset was also recorded. IBD activity was clinically evaluated by the Mayo Clinic score and the Harvey-Bradshaw Severity Index for patients with UC and CD, respectively [14] . Enrolled patients received a physical examination and medical history was collected. After insertion of a peripheral venous line for biological therapy, blood samples for routine laboratory tests and H. pylori serology were obtained.
Inclusion criteria for IBD patients were the presence of a confirmed IBD and a written informed consent. Patients with missing written informed consent were excluded from the analysis.
Controls that received H. pylori eradication therapy less than 12 months before enrollment were excluded from matching, as cases of new-onset IBD reported in the literature were diagnosed 6-12 months after eradication therapy.
Study participants who were seropositive for H. pylori infection and/or self-reported previous H. pylori infection and successful eradication therapy were considered H. pyloripositive. We chose this definition to include the largest number of patients with current or past H. pylori infection.
The study was conducted according to the Declaration of Helsinki [15] and approved by the Ethics Committee of the Otto-von-Guericke University Hospital of Magdeburg (protocol number 80/11).
H. pylori serology Serum samples of patients and controls were analyzed using an enzyme-linked immunosorbent assay for the presence of immunoglobulin G (IgG) both against H. pylori in general and specific for the CagA antigen of H. pylori as described previously [16] . Subjects with specific anti-H. pylori titer >30 EIU and/or anti-CagA titer >6.25 U/mL were classified as H. pylori positive.
Statistical analysis
Sample size calculation with a power of 80% and a desired significance level of 5% was performed with an online calculator (http://osse.bii.a-star.edu.sg/calculation1.php). Given that the eradication rate in the cohort of 516 blood donors was of 5.4% and the number of cases eradicated before IBD onset unknown, the sample size needed for cases and controls in a 1:2 fashion was 105 and 210, respectively.
Distribution of the demographic characteristics and related factors were compared by the Mann-Whitney U test for continuous data and by Fisher´s exact test for categorical variables, which were performed using an online calculator (https://www.graphpad.com/quickcalcs/ttest1.cfm). A statistical p value of 0.05 (two sided) was considered significant for all comparisons. For the analysis of the association between H. pylori infection and IBD onset, estimated odds ratios (OR) with corresponding 95% confidence intervals (CIs) were calculated (https://www.easycalculation.com/statistics/odds-ratio.php).
RESULTS
Epidemiological data
Overall, 127 consecutive patients with IBD (71 M: 56 F, median age 42, mean age 40.12±12.01 years, range 18-72 years) were prospectively enrolled between December 2016 and May 2017. A detailed description of demographics, medical therapy and clinical score of IBD patients at enrollment is reported in Table I . Ninety of them had CD (34 M: 56 F, mean age 41.5±12.02 years, range 18-72 years), 37 had UC (22M: 15 F, mean age 42±11.98 years, range 18-67 years) and none had unclassified IBD (IBDU). Fifteen IBD patients (10 CD and 5 UC) had a mild disease, defined by a Mayo Clinic score of 2 to 5 points and a Harvey-Bradshaw Severity Index of 6 or 7 points. All other IBD patients were in clinical remission (Mayo Clinic score of less than 2 points and a Harvey-Bradshaw Severity Index lower than 5). Table II . All patients and controls were German, living in Magdeburg or its neighborhood, in the constituent state of Saxony-Anhalt. No differences were observed in the number of siblings between IBD patients and controls. In the subgroup analysis comparing UC and CD there were no differences with respect to sex, age and number of siblings (Table III) .
We further performed a subgroup analysis comparing both CD and UC patients with sex-and age-matched controls. In either sub-analyses of CD or UC patients no differences were found with respect to the number of siblings compared to controls (Table IV and V, respectively).
Previous H. pylori eradication The rate of previous H. pylori eradication therapy in patients who thereafter developed an IBD was lower but not statistically different from that observed in the control group (3% and 7%, respectively, OR 0.43, 95% CI 0.14-1.29, p=0.16).
Only 4 out of 127 patients developed an IBD (3 CD and 1 UC) after H. pylori eradication therapy. Detailed records of these four patients are reported in Table VI . Indications for H. pylori testing and eradication therapy previously to IBD onset were epigastric pain (N=2), bloating (N=1) and heartburn (N=1). In three out of four patients H. pylori gastritis was diagnosed by esophagogastroduodenoscopy with biopsies. In one patient the general practitioner made the diagnosis of H. pylori infection by serology only (not in line with guidelines). In all four patients, eradication therapy was prescribed by their general practitioner. The latency between H. pylori eradication therapy and IBD onset was of 6 to 12 months.
IBD patients and controls with previous H. pylori infection were eradicated according to the current German [17] and European [18, 19] guidelines and to the local clarithromycin resistance rate (less than 15%) [20] . In particular, all controls and all but two IBD patients were eradicated before 2016 and received a clarithromycin-based triple therapy for 7 days, whereas two IBD patients received eradication in 2016 and 2017 with a 14-day clarithromycin-based triple therapy and a 10-day quadruple therapy with Pylera® and omeprazole, respectively.
Successful eradication was documented by 13 C-urea breath test or H. pylori stool antigen test in all study participants. In the subgroups analysis of CD patients, a negative association with both H. pylori antibodies (OR 0.33, 95% CI 0.14-0.74, p=0.004) and with CagA IgG (OR 0.29, 95% CI 0.08-1.01, p<0.005) was found (Table IV) . In addition, in the subgroup analysis of UC patients a negative association between IgG against H. pylori and UC (OR 0.4, 95% CI 0.19 to 0.82, p<0.01) was found. However, no association was observed between CagA seropositivity and UC (OR 0.72, 95% CI 0.18-2.92, p= 0.74, Table V) .
DISCUSSION
In our study IBD onset was not associated with a previous H. pylori eradication therapy. However, four of our IBD patients received H. pylori eradication therapy prior to definitive IBD diagnosis. The hypothesis that profound changes of gut microbiota composition induced by H. pylori eradication therapy (two antibiotics plus a PPI) may contribute, in a subset of individuals and under certain circumstances, to the development of IBD is fascinating. Metagenomic studies demonstrated an uneven recovery of the human gut microbiome after treatment with antibiotics [21] [22] [23] . Furthermore, in a subset of subjects with lower initial microbiome diversity, recovery of gut microbiome 3 months after antibiotic therapy was characterized by enrichment in opportunistic pathogens [24] .
In line with the 3 case reports available in the literature, the time frame for the development of IBD after eradication therapy was 6-12 months also in our four patients. This finding was also consistent with the results of a population-based casecontrol study that used the Rochester Epidemiology Project of Olmsted County (Minnesota) [25] . In this study the use of antibiotics was associated with an increased risk of developing both new-onset CD and UC and the risk was highest in the first year after antibiotic intake. One may speculate that "predisposed" subjects with lower initial microbiome diversity who receive antibiotic therapy may require at least 6-12 months for developing a clinically evident IBD. Thus, assessing prospectively microbiota prior and subsequent to H. pylori eradication therapy might be helpful for understanding the role of microbiota in relation to IBD onset.
The regimen used for H. pylori eradication therapy may also play a role for the hypothesized IBD risk. In particular, all the reported IBD cases developed following a clarithromycinbased triple therapy, whereas no cases of new-onset IBD have been described after quadruple bismuth-based eradication therapy. Indeed, at least for what metronidazole and the risk of IBD concerns, available data are inconsistent [26, 27] .
The loss of H. pylori induced immune response may play a role in increasing the susceptibility to develop IBD as well. In an animal model of Mongolian gerbils [28] , H. pylori infection induced a microbiota shift that became exclusively overt in the large intestinal tract although no histopathological changes of the intestinal mucosa were detected. Hence, loss of H. pylori induced alteration of the stomach might trigger large intestinal microbiota changes predisposing to the development of IBD. The rate of patients receiving H. pylori eradication therapy before IBD onset in our study was very low and less than half of the rate observed in the control group. Thus, on a population scale, the benefit deriving from the cure of H. pylori infection overwhelms the hypothetical risk of developing an IBD.
In line with previous studies [9] , we found a negative inverse association between H. pylori infection and IBD. Epidemiological studies in human populations have documented an inverse association between H. pylori infection and the risk of developing allergic diseases as well [29, 30] . The postulated protective effect of H. pylori infection against allergic diseases and possibly IBD may be mediated by regulatory T cells. Indeed, H. pylori is typically acquired during early childhood and the immunological tolerance towards H. pylori is driven by inducible regulatory T cells which are also required for the suppression of allergen-specific immune responses [31] [32] [33] .
Recently, Lord et al. [34] reported that the inverse association of H. pylori with IBD was restricted to the CagApositive strain and observed a protective effect of CagA only on CD. In our study, a negative inverse association between CagA status and IBD could not be confirmed, possibly as a consequence of the smaller number of IBD patients included.
All our IBD patients were under a biological therapy. It is unclear whether the negative association of H. pylori seroprevalence and IBD is confounded by other variables, such as immunosuppressive therapy or environmental factors. This aspect is currently under scrutiny at our site.
A strength of our study was the selection of controls from a well-characterized cohort of blood donors from the same region (Saxony-Anhalt, Germany) as the IBD group and tested both for the anti-H. pylori IgG in general and specific for the CagA antigen. In addition, in both IBD and control groups, information on previous H. pylori treatment was retrieved.
A limitation of the present study is the missing data on prior antibiotic use. However, this information is not reliable when collected on a patient´s history basis and we had no access to the prescription data of physicians who took care of our patients prior to IBD diagnosis. Whether previous antibiotic treatments may have increased the susceptibility of our patients to develop IBD after H. pylori eradication therapy cannot be excluded.
Based on previous case-reports and population-based studies we excluded controls who received eradication therapy less than 1 year before enrollment. As an increased risk of developing IBD may persist till up to 5 years after antibiotic treatment, the development of an IBD in our controls later on cannot be excluded [25, 26] .
CONCLUSION
In our study population, previous H. pylori eradication therapy was not associated with an increased risk of developing IBD. Our data should reassure physicians when prescribing H. pylori eradication therapy. Further studies are warranted to address the question as to whether H. pylori eradication therapy (the loss of H. pylori induced immune response or the combination of two antibiotics and a proton pump inhibitor) may trigger IBD development in a specific subgroup of patients.
